Greenwich LifeSciences, Inc.
GLSI
Rank in Stocks
#15819
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical... Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
Share Price
$16.52
Last synced: 2026-11-09
Market Cap
$242.48M
Change (1 day)
8.90%
Change (1 year)
95.04%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Greenwich LifeSciences, Inc. (GLSI)
Category
Healthcare
EPS for Greenwich LifeSciences, Inc. (GLSI)
EPS as of June 2026 TTM: $-1.54
According to Greenwich LifeSciences, Inc.'s latest financial reports, its current EPS (TTM) is $-1.54. At the end of 2025 the company had an EPS of $-1.43, a decrease compared to its 2024 EPS of $-1.21.
EPS history for Greenwich LifeSciences, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.54 | 7.69% |
| 2025 | $-1.43 | 18.18% |
| 2024 | $-1.21 | 75.36% |
| 2023 | $-0.69 | 13.11% |
| 2022 | $-0.61 | 74.29% |
| 2021 | $-0.35 | 133.33% |
| 2020 | $-0.15 | -48.28% |
| 2019 | $-0.29 | 107.14% |
| 2018 | $-0.14 | 7.69% |
| 2017 | $-0.13 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,116.88% |
US
|
|
| $-7.07 | 359.09% |
US
|
|
| $-5.29 | 243.51% |
AU
|
|
| $12.88 | -936.37% |
BE
|
|
| $21.56 | -1,500.00% |
NL
|
Questions about Greenwich LifeSciences, Inc.'s earnings per share (EPS)
What is Greenwich LifeSciences, Inc.'s earnings per share (EPS)?
Greenwich LifeSciences, Inc.'s earnings per share (EPS) over the last twelve months is $-1.54, as of Jun 2026.
What was Greenwich LifeSciences, Inc.'s earnings per share (EPS) in 2025?
In 2025, Greenwich LifeSciences, Inc.'s earnings per share (EPS) was $-1.43, compared with $-1.21 in 2024.
How has Greenwich LifeSciences, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Greenwich LifeSciences, Inc.'s earnings per share (EPS) was highest in 2020 ($-0.15) and lowest in 2025 ($-1.43).
How does Greenwich LifeSciences, Inc.'s earnings per share (EPS) compare with similar companies?
Greenwich LifeSciences, Inc.'s earnings per share (EPS) ($-1.54) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.